A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m(2) for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC) Meeting Abstract


Authors: Fury, M. G.; Sherman, E. J.; Lisa, D. M.; Agarwal, N.; Algazy, K. M.; Brockstein, B.; Langer, C. J.; Lim, D.; Mehra, R.; Rajan, S. K.; Jafri, N.; Korte, S.; Lipson, B.; Yunus, F.; Tanvetyanon, T.; Smith-Marrone, S.; Ng, K. K.; Xiao, H.; Haque, S.; Pfister, D. G.
Abstract Title: A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m(2) for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
Meeting Title: 47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 29
Issue: 15 Suppl.
Meeting Dates: 2011 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2011-05-20
Language: English
ACCESSION: WOS:000208880301704
DOI: 10.1200/jco.2011.29.15_suppl.5563
PROVIDER: wos
Notes: Meeting Abstract: 5563 -- Source: Wos
Altmetric Score
MSK Authors
  1. Han Xiao
    22 Xiao
  2. Kenneth K Ng
    36 Ng
  3. Eric J Sherman
    152 Sherman
  4. Sofia S Haque
    77 Haque
  5. David G Pfister
    251 Pfister
  6. Matthew G Fury
    93 Fury
  7. Brynna Lane Lipson
    8 Lipson
  8. Susan H Korte
    5 Korte
  9. Donna Lisa
    12 Lisa